Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.58 |
| ▸ | CDC25B | P30305 | 5/20 | 0.53 |
| ▸ | ACP1 | P24666 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356857 | 0.78 | PTPN1 (0.62) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL17748526 | 0.76 | PTPN1 (0.56) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL14194487 | 0.76 | PTPN1 (0.57) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL20351495 | 0.76 | PTPN1 (0.56) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL20826561 | 0.74 | PTPN1 (0.86) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL7114676 | 0.74 | PTPN1 (0.74) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL3590452 | 0.74 | PTPN1 (1.00) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL1028277 | 0.73 | PTPN1 (0.53) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL12332317 | 0.73 | PTPN1 (0.53) | PTPN1CDC25BACP1L3MBTL1ALDH1A1 | |
| SCHEMBL12018164 | 0.71 | POLB (0.41) | ALDH1A1CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743174-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | Aconcagua Bio, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO, INC. | 2025-02-06 | — | — | US | disclosed |
| WO-2025015268-A1 | MODULATORS OF CALCITONIN RECEPTOR AND/OR AMYLIN RECEPTOR ACTIVITY | ACONCAGUA BIO, INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| US-11801242-B2 | Compositions and methods for adjuvant cancer therapeutics | DUKE UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-11801242-B2 | Compositions and methods for adjuvant cancer therapeutics | DUKE UNIVERSITY (US) | 2023-10-31 | — | — | US | disclosed |
| US-20220008408-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | DUKE UNIVERSITY (US) | 2022-01-13 | — | — | US | disclosed |
| US-7396936-B1 | Modulators of calcitonin and amylin receptor activity | KEMIA, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396936-B1 | Modulators of calcitonin and amylin receptor activity | KEMIA, INC. (US) | 2008-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008408-A1 | COMPOSITIONS AND METHODS FOR ADJUVANT CANCER THERAPEUTICS | TP53, PLK1, NRAS | PTPN1 2014/4885CDC25B 462/4885ACP1 619/4885 |
| US-11801242-B2 | Compositions and methods for adjuvant cancer therapeutics | TP53, PLK1, NRAS | PTPN1 2014/4885CDC25B 462/4885ACP1 619/4885 |
| US-20250042916-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | IAPP, GIPR, GPR119 | PTPN1 1772/4885CDC25B 4381/4885ACP1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.